Oncotherapeutics
9201 Sunset Boulevard
Suite 317
West Hollywood
California
90069
United States
Tel: 310-623-1200
Fax: 310-623-1121
Website: http://www.oncotherapeutics.com/
Email: info@oncotherapeutics.com
3 articles about Oncotherapeutics
-
Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Results from the I-RUX Study Published in ASH2020
1/20/2021
- ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only steroids is well tolerated and shows promising efficacy for treating heavily previously treated MM patients.
-
Oncology CRO Oncotherapeutics Selects David Donahue as New Senior Director of Clinical Operations in Los Angeles, California
6/11/2009
-
Oncotherapeutics Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
2/12/2009